Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer - Jang, JoungSoon; Kim, Hoon-Kyo; Cho, Byoung Chul; Lee, Kyung Hee; Yun, Hwan-Jung; Woo, In Sook; Song, Hong Suk; Ryoo, Hun-Mo; Kim, Chi-Hong; Sun, Der-Sheng; Shin, Jong Wook (Cancer chemotherapy and pharmacology, 2017)
Keywords: adenocarcinoma; Adult; Aged; Aged, 80 and over; anemia; Antimetabolites, Antineoplastic - administration & dosage; Antineoplastic Agents - administration & dosage; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Carcinoma, Non-Small-Cell Lung - drug therapy; cisplatin; Cisplatin - administration & dosage; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; disease control; Disease-Free Survival; drug therapy; elderly; Female; Humans; Karnofsky Performance Status; lung neoplasms; Lung Neoplasms - drug therapy; Male; Maximum Tolerated Dose; Medicine; Medicine & Public Health; Middle Aged; neutropenia; Oncology; Original Article; Pharmacology/Toxicology; pneumonia; sample size; squamous cell carcinoma; Taxoids - administration & dosage; thrombocytopenia; toxicity; Gemcitabine; Elderly patients; Cisplatin; Non-small cell lung cancer; Docetaxel